• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding Ltd (OP: RHHBF )

    333.09 +7.79 (+2.39%)
    Streaming Delayed Price Updated: 10:42 AM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding Ltd

    < Previous 1 2 3 4 5 6 7 Next >
    WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
    Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
    Via Benzinga
    No More Free COVID-19 At-Home Tests, Federal Government Says
    CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
    Via Benzinga
    Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
    Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
    Via Benzinga
    FDA Approves Expanded Use Of Roche's Influenza Treatment
    Via Benzinga
    China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
    Via Benzinga
    Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
    Via Benzinga
    Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
    Via Benzinga
    Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field
    Via Benzinga
    Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
    Via Benzinga
    Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
    Via Benzinga
    Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
    Via Benzinga
    New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
    Via Benzinga
    Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
    Via Benzinga
    The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
    Via Benzinga
    Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
    Via Benzinga
    Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
    Via Benzinga
    Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
    Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung... 
    Via Benzinga
    Roche Releases More Evrysdi Data For Very Young Infants With SMA
    Via Benzinga
    Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
    The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine. 
    Via Benzinga
    COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
    Via Benzinga
    EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
    Via Benzinga
    FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
    The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
    Via Benzinga
    Read Why Pliant Therapeutics Shares Are Soaring Today
    Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. 
    Via Benzinga
    Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
    Via Benzinga
    FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
    Via Benzinga
    Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
    Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)  
    Via Benzinga
    Drug makers, Scientists Working For Long COVID Treatments: Reuters
    Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
    Via Benzinga
    Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.